Noramco to manufacture CBD to be delivered via the eye

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Batke)
(Image: Getty/Batke)

Related tags: CBD, Cannabidiol, Noramco, Nemus Bioscience

Noramco partners with Nemus to produce an analogue of cannabidiol that possesses greater bioavailability, that could be used to treat diseases of the retina.

Nemus Bioscience secured the services of Noramco to manufacture and assist in the scale up process of its cannabidiol (CBD) analogue, cannabidiol-valine-hemisuccinate (CBDVHS).

Bill Grubb, chief innovation officer at Noramco, explained why the partnership was formed: “Noramco’s technical knowledge in cannabinoid process development and scale-up, as well as clinical manufacturing capabilities, were complementary to Nemus’ desire to bring novel, differentiated cannabinoid therapies to patients.”

He added that Nemus had been referred to work with Noramco by a ‘leading US university’ that specialises in cannabinoid research.

The analogue, itself, possesses greater bioavailability compared to CBD, according to results seen in initial animal studies by Nemus. The investigational compound was developed by the University of Mississippi, using amide ester bioengineering.

Nemus has licensed the technology to develop therapeutic options for diseases of the retina, such as macular degeneration and diabetic retinopathy. The greater bioavailability of the compound could allow it to penetrate into the posterior chamber of the eye, Nemus stated.

The aim is to scale up production of CBDVHS to conduct pre-clinical and clinical studies.

Josh Hoerner, MD of R&D and clinical solutions at Noramco, told us what this would entail, “There are a number of challenges with manufacturing a unique analogue of CBD. Some specific examples include taking a small-scale medicinal chemistry route and developing it into a robust and scalable manufacturing route, developing new analytical methods, and proving the stability of the new analogue.”

However, Hoerner outlined that Noramco had been able to address these challenges to produce a product suitable for parenteral drug delivery.

Grubb had previously told us​ that demand for CBD APIs is growing and he projected this would continue to grow over the next five years – pointing to potential compound annual growth rate of between 24% and 55%.

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers

Follow us

Products

View more